As preferred Tregs stimulation by native IL-2 is predominantly attributed to its affinity for IL-2 receptor α (IL-2Rα), IL-2 variants with compromised IL-2Rα-binding ability have emerged as novel agents for tumor immunotherapy (Jin et al., 2022, Rybchenko et al., 2023). The gene discussed is IL2RA; the disease is neoplasm.